Proteomics Exploration Reveals That Actin Is a Signaling Target of the Kinase Akt*
Franck Vandermoere, Ikram El Yazidi-Belkoura, Ikram El Yazidi-Belkoura, Yohann Demont, Christian Slomianny, Johann Antol, Jérôme Lemoine, Hubert Hondermarck

To cite this version:
Franck Vandermoere, Ikram El Yazidi-Belkoura, Ikram El Yazidi-Belkoura, Yohann Demont, Christian Slomianny, et al.. Proteomics Exploration Reveals That Actin Is a Signaling Target of the Kinase Akt*. Molecular and Cellular Proteomics, American Society for Biochemistry and Molecular Biology, 2007, 6 (1), pp.114-124. 10.1074/mcp.M600335-MCP200 . hal-03030200

HAL Id: hal-03030200
https://hal.archives-ouvertes.fr/hal-03030200
Submitted on 29 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Proteomics Exploration Reveals That Actin Is a Signaling Target of the Kinase Akt*

Franck Vandermoere‡§, Ikram El Yazidi-Belkoura‡, Yohann Demont‡, Christian Slomianny¶, Johann Anton‡, Jérôme Lemoine||** and Hubert Hondermarck‡ ‡‡

The serine/threonine kinase Akt is a key mediator of cell survival and cell growth that is activated by most growth factors, but its downstream signaling largely remains to be elucidated. To identify signaling partners of Akt, we analyzed proteins co-immunoprecipitated with Akt in MCF-7 breast cancer cells. Mass spectrometry analysis (MALDI-TOF and MS-MS) of SDS-PAGE-separated Akt co-immunoprecipitates allowed the identification of 10 proteins: α-actinin, valosin-containing protein, inhibitor K β, mortalin, tubulin β, cytokeratin 8, actin, 14-3-3σ, proliferating cell nuclear antigen, and heat shock protein HSP27. The identification of these putative Akt binding partners were validated with specific antibodies. Interestingly, the major protein band observed in Akt co-immunoprecipitates was found to be the cytoskeleton protein actin for which a 14-fold increase was observed in Akt-activated compared with non-activated conditions. The interaction between Akt and actin was further confirmed by reverse immunoprecipitation, and confocal microscopy demonstrated a co-localization specifically induced under growth factor stimulation. The use of wortmannin indicated a dependence on the phosphatidylinositol 3-kinase pathway. Using a phospho-Akt substrate antibody, the phosphorylation of actin on an Akt consensus site was detected upon growth factor stimulation, both in cellulo and in vitro, suggesting that actin is a substrate of Akt kinase activity. Interestingly, cortical remodeling of actin associated with cell migration was reversed by small interfering RNA directed against Akt, indicating the involvement of Akt in the dynamic reorganization of actin cytoskeleton germane to breast cancer cell migration. Together these data identify actin as a new functional target of Akt signaling. *Molecular & Cellular Proteomics 6:114–124, 2007.

The serine/threonine kinase Akt/PKB1 belongs to the cAMP-dependent protein kinase A/protein kinase G/protein kinase C (AGC) superfamily of protein kinases that share structural homology within their catalytic domain and have similar mechanisms of activation (1). Akt/PKB was initially identified by three independent groups based on its homology to protein kinases A and C and to the cellular homolog of the retroviral oncogene Akt (v-Akt). In mammals, three Akt/PKB genes have been identified, termed PKBα/Akt1, PKBβ/Akt2, and PKBγ/Akt3, located at chromosomes 14q32, 19q13, and 1q44, respectively.

The original discovery of Akt kinase as the cellular homolog of a viral oncogene already implied its pivotal role in cell growth and survival that, since then, has been verified in various cell systems, and Akt is increasingly regarded as a crucial player in cancer cell survival and growth (2). Akt overexpression is observed in various human cancers, and the Akt signaling pathways are now considered as realistic targets for cancer therapy (2). In breast tumor biopsies, Akt1 is frequently overexpressed in a high percentage of cells, whereas Akt2 expression is mostly sparse; in contrast, most normal breast epithelial cells do not overexpress Akt kinases (3). Interestingly it has been suggested that activation of Akt1 by Her2/ phosphatidylinositol 3-kinase (PI3K) plays an important role in mediating multidrug resistance in human breast cancer cells, and Akt may therefore be a novel molecular target for therapies against breast cancer (2, 4). Akt protein modulates the function of several downstream substrates involved in the regulation of cell survival, cell cycle progression, and cellular growth. The list of proteins known to interact with Akt includes Bad, CAMP-response element-binding protein, the forkhead family, inhibitor KB kinase, procaspase-9, apoptosis signal-regulating kinase 1 (ASK1), murine double minute 2 (Mdm2), glycogen synthase kinase 3, p21Gip−/−/Cip−/−, a mammalian target of rapamycin (mTOR), and a tuberous sclerosis complex (TSC2) (5). The PI3K pathway that is stimulated by a wide range of tyrosine kinase growth factor receptors is the major activator of Akt signaling via stimulation of PDK1 that phosphorylates and activates Akt. The PI3K inhibitors LY294002 and wortmannin, both inhibiting the catalytic site of the p110 subunit, have routinely been used as research tools and are blast growth factor-2; PI3K, phosphatidylinositol 3-kinase; MEM, minimum essential medium; PDK1, phosphoinositide-dependent protein kinase 1; PAS, phospho-Akt substrate; siRNA, small interfering RNA; PH, pleckstrin homology; PCNA, proliferating cell nuclear antigen.
known to inhibit tumor growth in vivo (6). As the PI3K catalytic domain is highly conserved among PI3K family members, it is not surprising that either compound discriminates among the various isoforms of PI3K. Another potentially powerful strategy for inhibiting Akt is to disrupt the binding of its PH domain to 1,4,5-triphosphate phosphoinositide, thereby preventing its membrane translocation and activation by PDK1. Novel analogs of the 1,4,5-triphosphate phosphoinositide ring have been shown to be effective Akt inhibitors in cell culture (7). Because only a subset of the cellular processes regulated by the PI3K/Akt pathway are involved in tumorigenesis, the choice of drug targets must take into account the adverse effects resulting from the inhibition of other PI3K/Akt-dependent cellular processes. Therefore it would be desirable to identify and target components of branches further downstream in the PI3K/Akt pathway.

In this work, we used a proteomics-based approach to explore Akt signaling. Akt-co-immunoprecipitated proteins were analyzed by mass spectrometry, and a series of putative signaling partners were defined. Interestingly the cytoskeleton protein actin was found to be the major partner interacting with Akt under condition of growth factor stimulation. Akt-actin interaction resulted in actin cytoskeleton cortical remodeling associated with cell migration, revealing actin as a functional target of Akt signaling.

**EXPERIMENTAL PROCEDURES**

**Materials**—Cell culture reagents were purchased from BioWhittaker. Boyden microchambers (Transwell®) were from Costar. Recombinant human fibroblast growth factor-2 was from R&D Systems. Wortmannin (PI3K inhibitor) was from Calbiochem; G250 Coomassie Brilliant Blue, DMSO, and peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin G antibody were from Sigma. Antibodies against Akt/PKB (rabbit immunoaffinity-purified IgG), α-actinin-4, vavlosin-containing protein, inhibitor x kinase β, mortalin, tubulin β, cytokeratin 8, heat shock protein 27, and anti-panactin were from Upstate Biotechnologies. Anti-proliferating cell nuclear antigen was from Dianova Biotech. siRNA against Akt was obtained from Dharmacon.

**Cell Culture**—Breast cancer cell line MCF-7 was obtained from the American Type Culture Collection and routinely grown as monolayers. Cells were grown as described previously (8) at 37 °C in a humidified atmosphere of 5% CO2 in minimal essential medium (MEM)-Earle’s salts supplemented with 20 mM Hepes, 2 g/liter sodium bicarbonate, 2 mM L-glutamine, 1% non-essential amino-acids, 10% FCS, 100 units/ml penicillin/streptomycin, and 50 μg/ml gentamicin.

**Co-immunoprecipitation of Akt and Interacting Proteins**—The protocol used for identification of Akt binding partners is summarized in Fig. 1A. MCF-7 cells were rinsed in PBS, pH 7.5, serum-starved for 3 h in MEM-Earle’s salts, and treated by 10 μM Ba2+ceramide (Sigma) in fresh minimal essential medium. Proteins were extracted from cells after 15 min of 5 ng/ml FGF-2 stimulation. To inhibit PI3K/Akt, cells were pretreated for 3 h by 100 nM wortmannin before FGF-2 stimulation. Then cells were rinsed with PBS, pH 7.5, and scratched in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 0.1% SDS, 1% Nonidet P-40, 100 μM sodium orthovanadate). After centrifugation (10,000 × g for 5 min), proteins were quantified using the Bradford method (Bio-Rad). Akt and interacting proteins were co-immunoprecipitated from 15 mg of total proteins, using antibodies covalently bound on magnetic beads according to the Dynal Biotech protocol, using 50 μg of antibody with an incubation overnight at 4 °C. Co-immunoprecipitated proteins were rinsed three times with PBS, pH 7.5, before boiling for 5-min Laemmli buffer. Co-immunoprecipitations were reproduced five independent times.

**Gradient Electrophoresis**—Akt and interacting proteins that were co-immunoprecipitated as described above were solubilized in SDS solution (0.3% SDS and 1% ρ-mercaptoethanol). After migration, the gels were fixed (50% ethanol, 0.2 M orthophosphoric acid), and proteins were detected with colloidal blue staining (1 h in a mixture of 30% methanol, 0.2 M orthophosphoric acid, 170 g/liter ammonium sulfate before incubation in the same solution containing 0.66 g/liter G250 Coomassie Brilliant Blue). Band densities were quantified using Quanti-One software (Bio-Rad).

**Protein Identification by Mass Spectrometry**—Protein identifications were performed by MALDI-TOF and MS-MS. The protein bands of interest were trypsin-digested as described previously (8). MALDI- TOF and MS-MS analysis of the trypsin digests were performed on a Voyager reflector instrument (Applied Biosystems) and a Q-STAR mass spectrometer (Perseptive Biosystems) in positive ion mode. For mass fingerprint analysis, each raw spectrum was opened in Voyager Data Explorer software (version 4.6) and treated using advanced base-line correction and noise removal 2 functions. It was calibrated with two peptides resulting from trypsin autolysis (m/z 842.5100 and 2211.1046). Filter peak list for monoisotopic masses only was enabled, the peak detection threshold was manually adjusted over the background, and then the peak list was copied to Mascot public interface and searched against Swiss-Prot database 49.0 (268,833 sequences, 123,649,849 residues) using the following parameters: trypsin as enzyme, two possible missed cleavages, oxidized methionine as variable modification, MH+-monoisotopic masses, and peptide tolerance of 50 ppm. Results were scored using probability-based Mowse score (Protein score is −10log(p) where p is the probability that the observed match is a random event. Protein scores greater than 67 are significant (p < 0.05)). For MS-MS sequence information, each raw file was opened with Analyst Data software (version 1.4.1) and manually sequenced. Neutral mass of the precursor and sequence information were used to identify proteins in the Swiss-Prot database through Mascot public interface using a mass tolerance of 1 Da for precursor, trypsin as digestion enzyme, two possible missed cleavages, and oxidized methionine as variable modification. Results were scored using probability-based Mowse score (Protein score is −10log(p) where p is the probability that the observed match is a random event. Protein scores greater than 66 are significant (p < 0.05)).

**Western Blotting**—Co-immunoprecipitated proteins (corresponding to 500 μg of proteins subjected to immunoprecipitation) were separated by 10% SDS-PAGE. After electroblotting, nitrocellulose membranes were blocked by Tris-buffered saline, 0.1% Tween containing 6% bovine serum albumin for phospho-(Ser/Thr) Akt substrate antibody or 3% for other antibodies and probed with an appropriate antibody overnight at 4 °C. Then the membranes were rinsed and incubated with peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin G antibody (1 h at room temperature). After extensive washes, the reaction was revealed using the Super Signal West Pico chemiluminescent substrate (Pierce) with Eastman Kodak Co. X-Omat AR film.

**In Vitro Phosphorylation Assay**—2 μg of pure actin protein (Cytoskeleton, Inc.) was incubated for 30 min at 30 °C in a kinase buffer (25 mM Tris-HCl (pH 7.5), 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na4VO4, 10 mM MgCl2, 0.2 mM ATP) containing no enzyme or 200 ng of active Akt (Upstate), inactive Akt (Upstate), or PH domain.
deleted active Akt (Upstate). Then the reaction was stopped by boiling in Laemmli buffer, and phosphorylation was revealed by phospho-Akt substrate (PAS) Western blotting.

Transfection with siRNA—MCF-7 cells were incubated for 6 h in serum-free medium with a mixture of 5 μl of transfectant (siMPORTER®) and 150 nm SMART pools siRNA in MEM according to the manufacturer’s instructions (Upstate). Then 10% FCS was added directly to the medium. After 72 h, the cells were rinsed for 2 h in serum-free medium. The decrease in Akt protein level was assessed by Western blotting with anti-Akt antibody.

Confocal Microscopy—After FGF-2 stimulation, cells were successively rinsed with PBS, pH 7.5; fixed for 20 min with paraformaldehyde 4%; permeabilized for 20 min at room temperature with PBS, pH 7.5, 0.05% saponin, 50 mM ammonium chloride; and blocked for 30 min with PBS, pH 7.5, 0.05% saponin, 2% bovine serum albumin. Then cells were incubated for 2 h at room temperature in a blocking solution containing 1:200 phospho-Akt antibody, rinsed with PBS, pH 7.5, and incubated for 1 h at 37 °C in a blocking solution containing 1:3000 Alexa Fluor 546-goat anti-rabbit IgG and 1:500 Alexa Fluor 488-phalloidin (Invitrogen). Cells were mounted under Mowiol and observed through a Zeiss LSM510 confocal microscope. For studying cortical remodeling of actin, the same protocol using phalloidin was used after 6 h of growth factor stimulation. siRNA directed against Akt was transfected as described previously (9) 48 h before cell treatment by growth factor and visualization of actin cytoskeleton.

Migration Assays—Migration assays were done in 12-well Boyden microchambers (Transwell) with 12-μm-pore size membranes (Costar). The Transwells were first equilibrated with 1 ml of MEM for 1 h at 37 °C in 5% CO₂. The equilibration medium was then replaced by 1 ml of MEM supplemented or not with 5 ng/ml FGF-2 in the lower chambers, and 40,000 cells in 400 μl of MEM were loaded on the upper chambers. After a 24-h incubation, the Transwells were rinsed with PBS, and the upper surface of the membranes were scraped to remove cells. The cells remaining on the down side of the membrane were Hoechst-stained and mounted on glass sides with Glycergel (Dako) before counting (15 fields per membrane) under a UV microscope. Each condition was examined in quadruplicate.

RESULTS

Identification of Putative Akt Binding Partners—Co-immunoprecipitates obtained with Akt antibodies were resolved by SDS-PAGE (Fig. 1B). Two experimental conditions were compared. In the first Akt was not activated, and in the second Akt was activated by cell stimulation with FGF-2. After band cutting and trypsin digestion, α-actinin, valosin-containing protein, inhibitor kinase, mortalin, Akt1, tubulin β, cytokeratin 8, actin, 14-3-3ζ, proliferating cell nuclear antigen (PCNA), and heat shock protein HSP27 were identified by mass spectrometry. The identified proteins are listed in Table I, including the corresponding band number, protein name, accession number in the Swiss-Prot database, molecular mass, Mascot score, and percentage of coverage. The fact that neither the intensity of the Akt-corresponding band nor the intensity of the IgG-corresponding band changed from unstimulated to Akt-stimulated conditions was a reliable indication of equal loading. All identifications, primarily done by MALDI-TOF, were validated by sequencing with MS-MS and/or by Western blotting as indicated in Table I. The putative interactions were validated by Akt Western blotting on reverse immunoprecipitates (Fig. 2).
Reverse immunoprecipitation and Western blotting analysis. Reverse immunoprecipitations were performed with antibodies against proteins identified as putative partners of Akt (Fig. 1B and Table I) followed by Akt Western blotting. Variations of interaction were observed between unstimulated control situation (lane 1), Akt activation (by FGF-2 stimulation) without (lane 2) or with (lane 3) inhibition of PI3K/Akt by wortmannin (Akt inhibition). Potential phosphorylation on Akt consensus sites was tested using the PAS antibody. The reverse immunoprecipitation with actin antibodies is shown in Fig. 5.

**TABLE I**

Identification of putative Akt binding partners

Bands from gradient SDS-PAGE (Fig. 1) were digested by trypsin and analyzed by mass spectrometry through MALDI-TOF mass fingerprint and nano-ESI-MS-MS. For each identified protein, the following information is indicated: band number, protein name, accession number in Swiss-Prot database, molecular mass (MW), Mascot score for mass fingerprint and sequence-based identifications, percentage of protein sequence covered by the matched and sequenced tryptic fragments, mass difference between experimental and theoretical masses for MS-MS analysis, ratio of band intensity (volume on area representing the mean of five independent experiments), and recognition by PAS antibody.

| band | protein name | MW (kDa) | retention number | mass fingerprint | validation | MS/MS | ratio | CK8 (anti-IIα/8, H9252) | H9260 (anti-cytokeratin 8) | PAS antibody |
|------|--------------|----------|------------------|------------------|------------|-------|-------|----------------------|-------------------------|--------------|
| 1    | Alpha-actinin-4 | 104      | 0127707          | 362              | 469111 (66%) | antibody | 10.8  | yes                       | no                      |              |
| 2    | Vav-1 containing protein | 89      | P155973          | 114              | 188985 (35%) | MS/MS | WALKQNPSALSR | 661.1 | 128.49 | 0.4 | 138.2 | 5.7 | yes | yes | |
| 3    | LII kinase beta | 86      | 014420           | 96               | 917556 (115%) | antibody | 2.5   | yes                       | yes                     |              |
| 4    | Mortalin (GPR70) | 73      | P16406           | 385              | 129579 (99%) | antibody | 1.1   | no                       | no                      |              |
| 5    | Akt | 55      | P15749           | 182              | 155408 (25%) | MS/MS | EYVKARDEVAHSYLETIRE | 961.3 | 1923.01 | 1.1 | 220.2 | 1.0 | - | - | |
| 6    | Tubulin beta | 49      | P107437          | 81               | 124485 (33%) | antibody | 1.0   | no                       | no                      |              |
| 7    | Cytokeratin 8 | 48      | P103787          | 77               | 199482 (41%) | MS/MS | LIEEFAALQR | 565.9 | 1228.62 | 0.4 | 121.8 | 1.4 | no | no | |
| 8    | Actin beta/gamma | 42      | P1624191          | 218              | 189375 (47%) | MS/MS | EVELAPLSTMK | 581.2 | 160.61 | 0.1 | 160.5 | 1.1 | - | - | |
| 9    | Focal adhesion kinase | 28     | P102004          | 36               | 428151 (17%) | antibody | 593.2 | yes                       | yes                     |              |
| 10   | 14-3-3 sigma | 28      | P151477           | 70               | 55248 (22%) | antibody | 2.3   | yes                       | yes                     |              |
| 11   | Heat shock protein | 27    | P104792          | 113              | 742095 (35%) | antibody | 1.0   | no                       | no                      |              |

**Fig. 2.** Reverse immunoprecipitation and Western blotting analysis. Reverse immunoprecipitations were performed with antibodies against proteins identified as putative partners of Akt (Fig. 1B and Table I) followed by Akt Western blotting. Variations of interaction were observed between unstimulated control situation (lane 1), Akt activation (by FGF-2 stimulation) without (lane 2) or with (lane 3) inhibition of PI3K/Akt by wortmannin (Akt inhibition). Potential phosphorylation on Akt consensus sites was tested using the PAS antibody. The reverse immunoprecipitation with actin antibodies is shown in Fig. 5. WB, Western blotting; IP, immunoprecipitation; VCP, valosin-containing protein; IKKβ, inhibitor kB kinase β; CK8, cytokeratin 8.
FIG. 3. MALDI-TOF and MS-MS spectra corresponding to actin. Shown are MALDI-TOF (A) and MS-MS analyses (B–E) of band number 9 from gradient SDS-PAGE (Fig. 1B). The band was cut out of the gel and trypsin-digested. After MALDI-TOF and database searching, 21 tryptic peptides matched with theoretical masses leading to a sequence coverage of 42% provided a clear identification of β and γ actin that was confirmed by sequencing of four peptides by MS-MS.
Akt Interacts with Actin under Growth Factor Stimulation—
The most important difference observed between Akt-activated and non-activated conditions concerned protein band number 8 (Fig. 1B) that was found to be up-regulated 14-fold under FGF-2 stimulation. MALDI-TOF and MS-MS analysis allowed the clear identification of actin $\gamma$ and $\beta$ (Fig. 3 and Table II). By MALDI-TOF, 26 tryptic peptides matched with theoretical masses leading to a sequence coverage of 42% provided a clear identification of $\gamma$ and $\beta$ actin that was confirmed by sequencing of four peptides using MS-MS. Because non-dissociating buffer conditions were used to preserve protein-protein interaction during the immunoprecipitation it is likely that physiologically polymerized actin was also observed. In addition, confocal microscopy allowed the detection of a co-localization between polymerized actin (visualized with phalloidin) and Akt (detected with antibodies) under growth factor stimulation (Fig. 4). Activated Akt co-localized with actin cytoskeleton after 15 min of FGF-2 stimulation. Western blotting with anti-Akt antibody (Fig. 5A) confirmed the association between Akt and actin when it is phosphorylated. The results show that actin was recognized by PAS antibody under cell stimulation by FGF-2.

**Actin Is a Substrate of Phosphorylation by Akt—**The putative Akt partners identified here were screened with ScanSite software (52) to detect potential Akt phosphorylation sites. The best scores were obtained for putative phosphorylation sites in $\gamma$ actin, $\alpha$-actinin-4, inhibitor $\kappa$B kinase $\beta$, and cytokerin 8. Interestingly we detected phosphorylation of these consensus sites by using PAS antibody as predicted by computational analysis. The Akt-phosphorylated consensus site is commonly defined as RXRXD(S/T) (10, 11). In fact, the primary sequence of actin does not contain the precise consensus sequence predicted for an Akt substrate: the arginine at position $\sim 5$ is lacking. However, actin encodes a peptide sequence that is consistent with a pattern of other Akt-phosphorylated targets where arginine at position $\sim 5$ is not present as in insulin-response element-binding protein 1 (KERCQS$^{1036}$) (12), cAMP-response element-binding protein (LSRRPS$^{133}$Y) (13), and ATP-citrate lyase (TPAPSRTAS$^{455}$F) (14). The PAS antibody that we used here was raised against Akt RXRXD(pS/pT) (where pS is phosphoserine and pT is phosphothreonine) consensus sequence but does not appear to strictly require arginine in the $\sim 5$ position for phosphoprotein recognition as was obtained for ATP-citrate lyase (14). In actin, the putative phosphorylation sites corresponding to Akt consensus are APPERKYS$^{338}$ and ILTERGY$^{199}$. Actin immunoprecipitate was subjected to Western blotting with PAS antibody (Fig. 5B). This antibody detects the consensus site of Akt when it is phosphorylated. The results show that actin was recognized by PAS antibody under cell stimulation by FGF-2.

**Table II**

| MH$^+$ submitted | MH$^+$ matched | Delta mass | Missed cleavages | Peptide sequence consistent with mass |
|------------------|---------------|------------|-----------------|-------------------------------------|
| 976.48           | 976.44        | 0.03       | 0               | $^{19}$AGFAGDDAPR$^{28}$ |
| 1198.71          | 1198.70       | 0.01       | 0               | $^{29}$AVFPSVGRPR$^{39}$ |
| 1117.57          | 1117.56       | 0.01       | 0               | $^{40}$HQGVYGMVOK$^{50}$ |
| 1187.58          | 1187.56       | 0.01       | 0               | $^{40}$HQGVYGMVOK$^{50}$ |
| 1203.56          | 1203.55       | 0.00       | 0               | $^{40}$HQGVYGMVOK$^{50}$ |
| 1354.64          | 1354.62       | 0.02       | 1               | $^{51}$DSYVGEAO3SKR$^{62}$ |
| 800.54           | 800.53        | 0.01       | 1               | $^{62}$RGILTK$^{68}$ |
| 1515.75          | 1515.74       | $-0.00$    | 0               | $^{85}$WHHTFNYELR$^{95}$ |
| 1954.04          | 1954.06       | $-0.02$    | 0               | $^{96}$VAEEHPVLLTEAPLNPK$^{113}$ |
| 998.45           | 998.48        | $-0.03$    | 0               | $^{114}$DLTDYLMK$^{191}$ |
| 1132.54          | 1132.52       | 0.02       | 0               | $^{193}$GYSFTTAER$^{206}$ |
| 872.53           | 872.51        | 0.01       | 1               | $^{203}$EIVRDIK$^{213}$ |
| 1790.89          | 1790.88       | 0.01       | 0               | $^{239}$SYELPDGQITGNER$^{254}$ |
| 1548.82          | 1548.81       | 0.01       | 1               | $^{377}$MQEITALAPSTMK$^{392}$ |
| 1564.82          | 1564.80       | 0.01       | 1               | $^{313}$MQEITALAPSTMK$^{326}$ |
| 1161.62          | 1161.61       | 0.01       | 1               | $^{316}$EITALAPSTMK$^{329}$ |
| 1036.66          | 1036.64       | 0.01       | 1               | $^{327}$KIAAPPK$^{335}$ |
| 795.47           | 795.46        | 0.01       | 1               | $^{329}$KIAAPPK$^{335}$ |
| 923.57           | 923.56        | 0.01       | 0               | $^{360}$OEYDESGPSIVHRK$^{372}$ |
| 1516.71          | 1516.70       | 0.01       | 1               | $^{360}$OEYDESGPSIVHRK$^{373}$ |
| 1644.81          | 1644.79       | 0.01       | 1               | $^{360}$OEYDESGPSIVHRK$^{373}$ |
and that actin phosphorylation was inhibited by wortmannin, thereby indicating that actin is a phosphorylation target of Akt signaling. Nevertheless these data obtained with intact cells do not demonstrate a direct phosphorylation of actin by Akt as intermediary kinases could be involved. To investigate a potential direct phosphorylation of actin by Akt, an in vitro phosphorylation assay was performed. Recombinant Akt was mixed with actin and ATP. A phosphorylation of actin was detected by Western blotting with PAS antibody specifically when Akt was activated (Fig. 5C). No phosphorylation of actin was detected when Akt was not activated, and only a weak phosphorylation was observed with a PH domain-deleted form of Akt. At this stage, we were not able to directly map the regions of interaction and the phosphorylation sites, but our results suggest that Akt can phosphorylate actin in a PH domain-dependent manner.

**Fig. 4.** In situ validation of interaction between Akt and polymerized actin by confocal microscopy. MCF-7 breast cancer cells were stimulated for 15 min with 5 ng/ml FGF-2. Immunolocalization of phospho-Akt is revealed in red (antibody), and immunolocalization of actin is revealed in green (phallloidin-Alexa Fluor 488). Merge detection between Akt and polymerized actin appears in yellow, indicating a co-localization in the cortical submembrane area. The areas of co-localization are highlighted with white arrowheads. Antibody control consisted in the same experiment without anti-Akt antibody. Two different magnifications are displayed (a group of cells and one-cell zooms). White horizontal lines show scale bars for 20 μm.

**Fig. 5.** Phosphorylation of actin by Akt. A, reverse immunoprecipitation was performed with antibody against actin and followed by Akt Western blotting. Variations of interaction between actin and Akt were observed under growth factor stimulation with or without inhibition of PI3K/Akt by wortmannin. B, the same immunoprecipitates were used for Western blotting with PAS antibody, allowing the detection of actin phosphorylation under condition of Akt activation. C, in vitro phosphorylation assay was performed by incubating actin for 30 min at 30 °C in a reaction buffer containing either no enzyme, active Akt, inactive Akt, or PH domain-deleted active Akt. Phosphorylation of actin was revealed by Western blotting with PAS antibody. WB, Western blotting; IP, immunoprecipitation.
Akt Activation Induces Actin Cortical Remodeling and Is Necessary to Cell Migration—As pharmacological modulation of PI3K has been described to have an impact on the organization of actin cytoskeleton (15–17), we tested the potential implication of Akt in this process. Actin cytoskeleton was stained with phalloidin (Fig. 6A). FGF-2 cell stimulation induced an increase in cortical localization of actin that was inhibited by RNA interference against Akt, demonstrating an involvement of Akt in the actin cytoskeleton remodeling. In addition, the FGF-2-induced stimulation of MCF-7 cell migration, observed in Transwell experiments, was inhibited by siRNA against Akt (Fig. 6B) indicating the crucial role played by this kinase in the control of breast cancer cell migration. The efficiency of siRNA treatment in decreasing Akt level is shown in Fig. 6C.

**DISCUSSION**

In contrast to classical approaches to study signal transduction (based on the use of specific antibodies to identify signaling partners), proteomics offers the advantage of allowing the identification of unexpected partners, and this is of considerable potential for defining new therapeutic targets in pathologies such as breast cancer (18, 19). With co-immunoprecipitation and mass spectrometry-based methodology we identified new proteins potentially interacting with Akt. The immunoprecipitation-based methodology that we used has intrinsic limitations for access to the low concentration proteins, probably accounting for the fact that established partners of Akt signaling such as glycogen synthase kinase 3, forkhead, caspases, or Bad were not detected here. More generally, the development of more sensitive methods for analyzing signaling transduction pathways is clearly an issue in proteomics analysis (20). However, it is important to emphasize that no transfection or overexpression of Akt or any other partners were performed here, and therefore our study has the advantage to rely exclusively on physiological levels of protein expression and interaction.

Among putative partners of Akt identified in the present study, we have previously described the inhibitor xB kinase β (9) and the valosin-containing protein (21) as signaling targets of Akt in breast cancer cells. Some of the identified proteins were found to be constitutively associated with Akt as their interaction was not growth factor-regulated. This is for example the case for the molecular chaperone 14-3-3σ that targets phosphoproteins and regulates their activities (22). Expression of 14-3-3σ, which is induced in response to DNA damage and causes cells to arrest in G2, is lower in breast carcinoma cells than in normal breast epithelium due to frequent hypermethylation of the gene (8, 23). Interestingly it has been shown previously that 14-3-3σ might be a negative regulator of Akt signaling by masking its phosphorylation targets like tuberin (24), and our data reinforce the hypothesis of a functional interaction between 14-3-3σ and the Akt-mediated signaling. Other protein chaperones were identified, such as the heat shock protein HSP27 and mortalin. Although the potential interaction with Akt that we report here is in accordance with the oncogenic potentiality of these proteins, further experi-

![Fig. 6. Cortical remodeling of actin and cell migration are induced by Akt activation.](image-url)
ments would be necessary to confirm a functional interaction. The PCNA was also found as a putative Akt partner. PCNA was originally characterized as a DNA sliding clamp for replicative DNA polymerases and as an essential component of the eukaryotic chromosomal DNA replisome and turned out to interact with multiple partners involved in metabolic pathways, DNA repair, DNA synthesis and methylation, chromatin remodeling, and cell cycle regulation (25). At this stage, it cannot be ascertained whether Akt directly interacts with PCNA. Because one of the known interacting partners of PCNA is p21<sup>waf1</sup> (26), which is described as an Akt substrate, we can hypothesize that PCNA could have been co-immunoprecipitated with Akt due to p21 dual interaction. However, further experimentation would also be needed to clarify the potential interaction between Akt and PCNA. Few proteins identified in this study are components of the cytoskeleton. Tubulins, the building block of microtubules, are heterodimers comprising α and β subunits. Tubulin modifications have been reported in breast cancer and are linked to tumor aggressiveness (27). It has been shown that the level of modified tubulins increases in Taxol-resistant MCF-7 breast cancer cells (28), and the structure of tubulin complexed with Taxol has been described (29). Interestingly several kinases such as MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase), ERK (extracellular signal-regulated kinase), and p90RSK interact with tubulin to reorganize cytoskeleton and influence cell division or migration (30, 31), and our data suggest that Akt might belong to this category of tubulin-interacting proteins. However, it should be emphasized that, at this stage, the list of proteins that we established represents putative Akt interacting partners and that further biochemical and physiological analyses are required to validate the existence of functional interactions.

The major partner of Akt that we identified is the cytoskeleton component actin. The actin network is a rather complex structural and functional system of all eukaryotic cells that responds to multiple intracellular stimuli and contributes to cell-cell and cell-substrate interactions by providing a structural framework and by modulating signal transduction cascades (32). It also generates movements to carry out many fundamental cell processes, such as lamellipodial and growth cone extension, chemotaxis, endocytosis, exocytosis, and cytokinesis. Regulation of the actin cytoskeleton plays a central role in cell growth, differentiation, and motility and is correlated to cancer development and invasion. Actin remodeling can result from the activation of oncogenic signaling pathways (e.g. Ras and Src) or the inactivation of several actin-binding proteins that have tumor suppressor functions such as gelsolin (33). These changes are thought to be integrally involved in the abnormal growth properties of tumor cells, their ability to adhere to tissue, and their increased ability to metastasize. The family of p21-activated kinases has been implicated in the rearrangement of actin cytoskeleton by acting downstream of the small GTPase Rac under PI3K stimulation and resulting in the dissolution of stress fibers and the redistribution of microfilaments via cdc42 (34). It has been found that p21-activated kinase 1 is stimulated by activated Akt through a GTPase-independent mechanism as well as by PDK1 through a PI3K-independent mechanism (35). Another signaling adapter protein that has been reported to interact with actin is Src homologous and collagen (Shc). Shc binds to actin under growth factor stimulation, allowing the activation of downstream signaling leading to cell orientation toward proliferation versus differentiation (36). Similarly the phosphorylation of EDG-1 by Akt specifically regulates coupling to Rac activation, cortical actin changes, and chemotactant-induced cell migration. Akt phosphorylation of EDG-1 may constitute a “specificity switch” to cell migration. Actin remodeling through Akt activation was rather attributed to p70S6K, a downstream Akt signaling kinase (37). Here we have suggested that Akt is able to directly phosphorylate actin, adding further comprehensive information to PI3K/Akt-dependent regulation of actin organization.

The possibility that actin filaments and their regulatory proteins could be selectively targeted in cancer chemotherapy is attractive (38). Interestingly gelsolin, an actin capping/severing protein, is commonly down-regulated in many tumor cells and functions as a tumor suppressor in breast epithelial cells (39, 40). Major cytoskeleton filaments, including actin, are degraded during the execution phase of apoptosis, and a direct link between actin depolymerization and DNA degradation has been suggested (41), leading to the idea that the derangements of actin filaments may, by themselves, initiate cell death signals (42, 43). Interestingly cytochalasin D, the best studied and most widely used agent that acts on actin and exerts a powerful effect on actin filaments, has been reported to enhance cytokine withdrawal and drug treatment-induced apoptosis (43, 44). In our experiments, confocal microscopy showed a substantial cortical reorganization of actin under condition of growth factor-activated Akt. Such cortical reorganization can be induced by PI3K stimulation (16), and Akt as downstream effector of PI3K constitutes a major effect in PI3K-mediated actin remodeling. Another cytoskeletal protein identified here is α-actinin-4, which is a non-muscle α-actinin isoform up-regulated upon enhanced cell movement (45, 46). Actinin-4 has been described as steadily shifting from the cytoplasm to the nucleus upon inhibition of PI3K or actin depolymerization; the cytoplasmic localization of actinin-4 was closely associated with an infiltrative histological phenotype and correlated significantly with a poorer prognosis of breast cancer (45). In our experiments, we found that actinin-4 interacts with Akt, but we did not detect any change
in phosphorylation of actinin-4 induced by Akt. Actinin-4 might not directly interact with Akt but could be associated with actin and therefore co-immunoprecipitated with it. Nevertheless it is interesting to note that regulation of actinin-4 is related to cell movement and migration, and in breast cancer, it has been reported that Akt mediates the invasive effect of growth factors (47). The relationship between Akt and the control of cell migration has been suggested by the demonstration that the PI3K/Akt pathway is involved in anchorage-independent growth and metastasis of liver cancer cells (48) similar to thyroid carcinoma cells (49). In addition, Akt mediates Ras down-regulation of RhoB, a suppressor of transformation, invasion, and metastasis (50). In breast cancer, it has been demonstrated that Akt is frequently expressed in a high percentage of tumor cells (3). Growth factor-induced metastasis gene expression in breast cancer has been shown to be related to Akt signaling (47), and moreover, the activation of Akt by Her2/PI3K plays an important role in mediating multidrug resistance in human breast cancer cells (4, 51). Our data, showing a corticoreorganization of actin associated with a stimulation of cell migration dependent on Akt activation, indicate a relationship with invasive capacities of breast cancer cells that is potentially germane to the metastatic process. However, it should be noticed that a direct link has not been proved here. Indeed Akt activates other downstream pathways, including for example Rac, that may also be responsible for mediating changes in invasive capacities of breast cancer cells.

In conclusion, our proteomics exploration of Akt signaling in breast cancer cells led to the demonstration that the cytoskeleton protein actin is a major cellular partner of this kinase. Cytoskeleton remodeling occurs at all levels of cell dynamics, and our data suggest that the many key regulatory functions played by Akt in cell physiology could be at least partly mediated through interaction with and subsequent phosphorylation of actin.

* This work was supported in part by the French Ministry for Research and Education, the INSERM, the “Ligue Nationale Contre le Cancer (Equipe labellisée 2006),” the “Region Nord-pas-de-Calais,” and the “Institut Universitaire de France”. The costs of publication of this article were defrayed in part by the payment of page charges.

** Present address: UMR CNRS 5180, Université Claude Bernard, 69622 Villeurbanne, France.

†† To whom correspondence should be addressed: ERI-8 INSERM, batiment SN3, Université des Sciences et Technologies de Lille, 59655 Villeneuve d’Ascq, France. Tel.: 33-3-20-43-40-57; Fax: 33-3-20-47-40-38; E-mail: hubert.hondermarck@univ-lille1.fr.

REFERENCES

1. Hanada, M., Feng, J., and Hemmings, B. A. (2004) Structure, regulation and function of PKB/AKT—a major therapeutic target. *Biochim. Biophys. Acta* 1697, 3–16

2. Luo, J., Manning, B. D., and Cantley, L. C. (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer Cell* 4, 257–262

3. Stal, O., Perez-Tenorio, G., Akerberg, L., Olsson, B., Nordenskjold, B., Skoog, L., and Rutqvist, L. E. (2003) Akt kinases in breast cancer and the results of adjuvant therapy. *Breast Cancer Res.* 5, R37–R44

4. Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelson, J. F., and Fan, Z. (2003) HER2/PIK3CA/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. *Oncogene* 22, 3205–3212

5. Downward, J. (2004) PI 3-kinase, Akt and cell survival. *Semin. Cell Dev. Biol.* 15, 177–182

6. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. (2002) Inhibition of phosphatidylinositol 3-kinase increases efficacy of paclitaxel in vitro and in vivo in ovarian cancer models. *Cancer Res.* 62, 1087–1092

7. Kozikowski, A. P., Sun, H., Brognard, J., and Dennis, P. A. (2003) Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. *J. Am. Chem. Soc.* 125, 1144–1145

8. Vercoutter-Edouart, A. S., Lemoine, J., Le Bourhis, X., Louis, H., Boîly, B., Nuncorome, V., Revillion, F., Peyrat, J. P., and Hondermarck, H. (2001) Proteomic analysis reveals that 14-3-3ζ is down-regulated in human breast cancer cells. *Cancer Res.* 61, 8403–8409

9. Vandermoere, F., El Yazidi-Belkoura, I., Adriaenssens, E., Lemoine, J., and Hondermarck, H. (2005) The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-κB activation induced via interaction between Akt and IkB kinase-β in breast cancer cells. *Onco gene* 24, 5482–5491

10. Alessi, D. R., Caudwell, F. B., Andjelkovic, M., Hemmings, B. A., and Cohen, P. (1996) Molecular basis for the substrate specificity of protein kinase B. *Proc. Natl. Acad. Sci. U.S.A.* 93, 1353–1357

11. Obata, T., Yaffe, M. B., Leparc, G. G., Piro, E. T., Maegawa, H., Kashiwagi, A., Kikkawa, R., and Cantley, L. C. (2000) Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. *J. Biol. Chem.* 275, 36108–36115

12. Villafuerte, B. C., Phillips, L. S., Rane, M. J., and Zhao, W. (2004) Insulin-responseselected substrate-binding protein 1: a novel Akt substrate involved in transcriptional action of insulin. *J. Biol. Chem.* 279, 36650–36659

13. Du, K., and Montminy, M. (1998) CREB is a regulatory target for the protein kinase protein kinase B. *J. Biol. Chem.* 273, 32377–32379

14. Berwick, D. C., Hers, I., Heesom, K. J., Moule, S. K., and Tavare, J. M. (1996) The identification of ATP-competitive lysine as a protein kinase B (Akt) substrate in primary adipocytes. *J. Biol. Chem.* 271, 33895–33900

15. Ma, A. D., Metjtan, A., Bagrodia, S., Taylor, S., and Abrams, C. S. (1998) Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase γ, a Rac guanosine exchange factor, and Rac. *Mol. Cell. Biol.* 18, 4744–4751

16. Hill, K., Wettl, S., Yu, J., Murray, J. T., Yip, S. C., Condeelis, J. S., Segall, J. E., and Backer, J. M. (2000) Specific requirement for the p85α/p110α phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells. *J. Biol. Chem.* 275, 3741–3744

17. Kang, K. W., Lee, S. J., Park, J. W., and Kim, S. G. (2002) Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. *Mol. Pharmacol.* 62, 1001–1010

18. Hondermarck, H. (2003) Breast cancer: when proteomics challenges biological complexity. *Mol. Cell. Proteomics* 2, 281–291

19. Hondermarck, H. (ed) (2004) Biomedical and Pharmaceutical Applications of Proteomics, Kluwer, Pogradec, The Netherlands

20. Kabuyama, Y., Resing, K. A., and Ahn, N. G. (2004) Applying proteomics to signaling networks. *Curr. Opin. Genet. Dev.* 14, 492–498

21. Vandermoere, F., El Yazidi-Belkoura, I., Slomiany, C., Demont, Y., Bidaux, G., Adriaenssens, E., Lemoine, J., and Hondermarck, H. (2006) The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. *J. Biol. Chem.* 281, 14307–14313

22. Mackintosh, C. (2004) Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. *Biochem. J.* 381, 329–342

23. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Heremeking, H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampfer, M. R., and Sukumar, S. (2000) High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer. *Proc. Natl. Acad. Sci.*
Actin Is a Target of Akt Signaling

24. Liu, M. Y., Cai, S., Espejo, A., Bedford, M. T., and Walker, C. L. (2002) 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res. 62, 6475–6480
25. Maga, G., and Hubsher, U. (2003) Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J. Cell Sci. 116, 3051–3060
26. Maga, G., Blanca, G., Shevelev, I., Frouin, I., Ramadan, K., Spadari, S., Villani, G., and Hubsher, U. (2004) The human DNA polymerase lambda interacts with PCNA through a domain important for DNA primer binding and the interaction is inhibited by p21/WAF1/CIP1. FASEB J. 18, 1743–1745
27. Mialhe, A., Lafanechere, L., Treileux, I., Peloux, N., Dumontet, C., Bremond, A., Panh, M. H., Payan, R., Wehland, J., Margolis, R. L., and Job, D. (2001) Tubulin deacetylation is a frequent occurrence in breast cancers of poor prognosis. Cancer Res. 61, 5024–5027
28. Banerjee, A. (2002) Increased levels of tyrosinated α-, β(III)-, and β(IV)-tubulin isoforms in paclitaxel-resistant MCF-7 breast cancer cells. Biochim. Biophys. Acta 1593, 598–601
29. Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H., and Nogales, E. (2002) Molecular & Cellular Proteomics 6.1
30. Willard, F. S., and Crouch, M. F. (2001) MEK, ERK, and p90RSK are present in regulating mitotic exit. Cell. Signal. 13, 653–664
31. Pellegrini, F., and Budman, D. R. (2005) Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 23, 264–273
32. Revenu, C., Athman, R., Robine, S., and Louvard, D. (2004) The co-workers of actin filaments: from cell structures to signals. Nat. Rev. Mol. Cell. Biol. 5, 635–646
33. Yin, H. L., and Stull, J. T. (1999) Proteins that regulate dynamic actin remodeling in response to membrane signaling minireview series. J. Biol. Chem. 274, 32529–32530
34. Papakonstanti, E. A., and Stournaras, C. (2002) Association of PI-3 kinase with PKA1 leads to actin phosphorylation and cytoskeletal reorganization. Mol. Biol. Cell 13, 2946–2962
35. King, C. S., Gardiner, E. M., Zenke, F. T., Bohi, B. P., Newton, A. C., Hemmings, B. A., and Bokoch, G. M. (2000) p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase (PDK1). J. Biol. Chem. 275, 41201–41209
36. Thomas, D., Patterson, S. D., and Bradshaw, R. A. (1995) Src homologous and collagen (Shc) protein binds to F-actin and translocates to the cytoskeleton upon nerve growth factor stimulation in PC12 cells. J. Biol. Chem. 270, 28924–28931
37. Qian, Y., Corum, L., Meng, Q., Blenis, J., Zheng, J. Z., Shi, X., Flynn, D. C., and Jiang, B. H. (2004) P3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am. J. Physiol. 286, C153–C163
38. Rao, J., and Li, N. (2004) Microfilament actin remodeling as a potential target for cancer drug development. Curr. Cancer Drug Targets 4, 345–354
39. Asch, H. L., Head, K., Dong, Y., Natoli, F., Winston, J. S., Connolly, J. L., and Asch, B. B. (1996) Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res. 56, 4841–4845
40. Silacci, P., Mazzolai, L., Gauci, C., Stergiopoulos, N., Yin, H. L., and Hayoz, D. (2004) Gelsolin superfamily proteins: key regulators of cellular functions. CMLS Cell. Mol. Life Sci. 61, 2614–2623
41. Kyril, G., Ord, T., Testa, M. P., Zhong, L. T., and Bredesen, D. E. (1996) Cleavage of actin by interleukin 1 β-converting enzyme to reverse DNase I inhibition. Proc. Natl. Acad. Sci. U. S. A. 93, 2234–2238
42. White, S. R., Williams, P., Wojcik, K. R., Sun, S., Hiemstra, P. S., Rabe, K. F., and Dorsch, D. R. (2001) Initiation of apoptosis by actin cytoskeletal derangement in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 24, 282–294
43. Morley, S. C., Sun, G. P., and Bierer, B. E. (2003) Inhibition of actin polymerization enhances commitment to and execution of apoptosis induced by withdrawal of trophic support. J. Cell. Biochem. 86, 1066–1076
44. Yamazaki, Y., Tsuruga, M., Zhou, D., Fujita, Y., Shang, Y., Kawasaki, K., and Oka, S. (2000) Cytoskeletal disruption accelerates caspase-3 activation and alters the intracellular membrane reorganization in DNA damage-induced apoptosis. Exp. Cell Res. 259, 64–78
45. Honda, K., Yamada, T., Endo, R., Ino, Y., Gotoh, M., Tsuda, H., Yamada, Y., Chiba, H., and Hirohashi, S. (1998) Actin-α, a novel actin-bundling protein associated with cell motility and cancer invasion. J. Cell Biol. 140, 1383–1393
46. Otey, C. A., and Carpen, O. (2004) α-Actinin revisited: a fresh look at an old player. Cell Motil. Cytoskelet. 58, 104–111
47. Zhang, G., He, B., and Weber, G. F. (2003) Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol. Cell. Biol. 23, 6607–6619
48. Nakanishi, K., Sakamoto, M., Yasuda, J., Takamura, M., Fujita, N., Tsuruo, T., Todo, S., and Hirohashi, S. (2002) Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogenous intrathoracic metastasis of liver cancer. Cancer Res. 62, 2971–2975
49. Kim, C. S., Vasko, V. V., Kato, Y., Kruhlak, M., Saji, M., Cheng, S. Y., and Ringel, M. D. (2005) AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 146, 4456–4463
50. Jiang, K., Sun, J., Cheng, J., Djeu, J. Y., Wei, S., and Sebti, S. (2004) Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol. Cell. Biol. 24, 5565–5576
51. Liang, K., Jin, W., Kruefelmann, C., Schmidt, M., Mills, B. G., Ang, K. K., Ringel, M. D., and Carpen, O. (2004) Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31, 3635–3641